# Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

> **NCT03990051** · PHASE2 · COMPLETED · sponsor: **Glia, LLC** · enrollment: 33 (actual)

## Conditions studied

- Chronic Ocular Graft-versus-host Disease

## Interventions

- **DRUG:** Pro-ocular™ topical gel
- **DRUG:** Placebo topical gel

## Key facts

- **NCT ID:** NCT03990051
- **Lead sponsor:** Glia, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-17
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-11-19
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03990051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03990051, "Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03990051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*